Purpose: The value of telomerase activity as a marker in clinical decision-
making is closely related to how representative the analysis of a small tum
or sample is for the whole tumor. We therefore evaluated the intratumoral d
istribution pattern of telomerase activity in prostatic carcinomas.
Materials and Methods: From 50 prostate cancer patients treated with radica
l prostatectomy, telomerase activity was determined using the telomeric rep
eat amplification protocol (TRAP assay). Comparative analysis of at least t
wo separate cancer areas from a single tumor was performed in 42 cases.
Results: Telomerase activation has been demonstrated in 90% of the prostati
c carcinomas. Focal intratumoral heterogeneity was found in 38.1% of the tu
mors with at least two different areas examined. Telomerase positivity of a
ll samples from one given tumor was detected in 50%, telomerase negativity
of all samples in 11.9%. A heterogeneous telomerase activity pattern was mo
re frequently detected in tumors with a Gleason score less than or equal to
7 than in those with a Gleason score >7. Furthermore, there was an increas
e in the proportion of homogeneously telomerase-positive tumors with increa
se in severity of the Gleason score. The differences reached statistical si
gnificance. Telomerase activity was also detected in non-cancerous prostati
c tissue samples.
Conclusions: Telomerase activation is nearly ubiquitous in prostatic carcin
omas, although a heterogeneous telomerase activity pattern within tumors mi
ght produce a false-negative result in the telomerase activity assay. This
limits the value of telomerase activity assays for diagnostic means. There
is evidence for a shift from telomerase-negative prostate cancer tissue tow
ard telomerase positivity during the progression process of prostate cancer
. The relatively high proportion of telomerase-positive nonmalignant prosta
tic tissue samples argues against cancer-specificity of telomerase activati
on.